Gregory Durm is an Oncology physician affiliated with Indiana University Health. OpenAlex indexes 34 publications with 3,665 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
26.3%Opioid Agonist7.8%Oxycodone-Acetaminophen52%Oxycodone Hcl48%Part D<11 patientsAtypical Antipsychotic7.3%Olanzapine100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
19.9%Serotonin-3 Receptor Antagonist11.6%Ondansetron Hcl72%Ondansetron Odt28%Part D<11 patientsProton pump inhibitor5.4%Omeprazole100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
16.7%Kinase inhibitor16.7%Retevmo39%Tagrisso24%Lorbrena19%Sunitinib Malate18%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2026 - Adverse COVID-19 experiences and physical and psychological outcomes in patients with lung cancer
Palliative & Supportive Care
2026 - NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
Journal of the National Comprehensive Cancer Network
2025 - Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Douglas Zipes, MD
Indiana University Health
Lawrence Einhorn, MD
Indiana University Health
Lisa Landrum, MD
Indiana University Health
Patrick Loehrer, MD
Indiana University Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”